Rhinocort Aqua Related Published Studies
Well-designed clinical trials related to Rhinocort Aqua (Budesonide Nasal)
Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis. [2007.06]
Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. [2006.05]
A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. [2006.05]
Activity of budesonide on nasal neutrophilic inflammation and obstruction in children with recurrent upper airway infections. A preliminary investigation. [2006.03]
The effect of intranasal steroid budesonide on the congestion-related sleep disturbance and daytime somnolence in patients with perennial allergic rhinitis. [2005.07]
[Nasal budesonide plus zafirlukast vs nasal budesonide plus loratadine-pseudoephedrine for controlling the symptoms of rhinitis and asthma] [2005.03]
Increased nasal airflow with budesonide compared with desloratadine during the allergy season. [2005.03]
Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus budesonide nasal spray in the management of nasal congestion in allergic rhinitis. [2005]
Well-designed clinical trials possibly related to Rhinocort Aqua (Budesonide Nasal)
Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis: a randomized controlled trial. [2007.12.05]
Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. [2006.04]
Single dose topical corticosteroid inhibits IL-5 and IL-13 in nasal lavage following grass pollen challenge. [2005.12]
Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. [2005.10]
Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. [2005.05]
Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy. [2005.05]
Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. [2005.04]
Other research related to Rhinocort Aqua (Budesonide Nasal)
Topical budesonide via mucosal atomization device in refractory postoperative chronic rhinosinusitis. [2008.07]
Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. [2008.06.09]
Methacholine-induced pulmonary gas trapping in a mouse model of allergic asthma: effect of inhaled budesonide and ciglitazone. [2008.01.06]
Efficacy of Odiosoft-Rhino in assessment of nasal obstruction: a comparative study with acoustic rhinometry after treatment with budesonide nasal spray in patients with perennial allergic rhinitis. [2007.11]
[Clinical observation on intranasal budesonide in chronic nonallergic rhinitis] [2006.01]
Resolution of nocturnal enuresis in snoring children after treatment with nasal budesonide. [2005.07]
Other possibly related research studies
Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. [2007.01]
Immunotherapy for patients with persistent allergic rhinitis unsatisfied with free chronic pharmacotherapy. [2006.05]
Severe nasal polyposis and its impact on quality of life. The effect of a short course of oral steroids followed by long-term intranasal steroid treatment. [2006.03]
Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids. [2006.04]
How do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis? [2005.12]
Evaluation of nasal barrier dysfunction at acute- and late-phase reactions in a guinea pig model of allergic rhinitis. [2005.10]
Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. [2005]
The influence of anti-inflammatory drugs on the proliferation of fibroblast derived from nasal polyps. [2005.09]
Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis. [2005.05]
Fracture risk associated with systemic and topical corticosteroids. [2005.04]
Rhinitis medicamentosa: a review of causes and treatment. [2005]
Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. [2005.03]
Topical glucocorticosteroids in rhinitis: clinical aspects. [2006.10]
Comparison of once-daily intranasal corticosteroids for the treatment of allergic rhinitis: are they all the same? [2006.01.25]
Montelukast decreased exhaled nitric oxide in children with perennial allergic rhinitis. [2007.06]
Nasal polyposis: role of allergy on therapeutic response of eosinophil- and noneosinophil-dominated inflammation. [2006.01]
Evaluation of efficacy of topical corticosteroid for the clinical treatment of nasal polyposis: searching for clinical events that may predict response to treatment. [2007.03]
Topical levamisole hydrochloride therapy attenuates experimental murine allergic rhinitis. [2007.12.22]
Corticosteroid therapy increases membrane-tethered while decreases secreted mucin expression in nasal polyps. [2008.06.10]
Abnormal spirometry in children with persistent allergic rhinitis due to mite sensitization: the benefit of nasal corticosteroids. [2008.02]
Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids. [2008.07.29]
A randomized prospective study comparing medical and medical-surgical treatment of nasal polyposis by CT. [2008.08.08]
Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids. [2008.10]
Corticosteroid therapy increases membrane-tethered while decreases secreted mucin expression in nasal polyps. [2008.10]
|
